Amber B. Koehler

812 total citations
29 papers, 338 citations indexed

About

Amber B. Koehler is a scholar working on Genetics, Pathology and Forensic Medicine and Gastroenterology. According to data from OpenAlex, Amber B. Koehler has authored 29 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Genetics, 16 papers in Pathology and Forensic Medicine and 6 papers in Gastroenterology. Recurrent topics in Amber B. Koehler's work include Chronic Lymphocytic Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (16 papers) and Gastrointestinal Tumor Research and Treatment (6 papers). Amber B. Koehler is often cited by papers focused on Chronic Lymphocytic Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (16 papers) and Gastrointestinal Tumor Research and Treatment (6 papers). Amber B. Koehler collaborates with scholars based in United States, Australia and United Kingdom. Amber B. Koehler's co-authors include Wei Ding, José F. Leis, Saad S. Kenderian, Timothy G. Call, Neil E. Kay, Eli Muchtar, Susan L. Slager, Sameer A. Parikh, Kari G. Rabe and Susan M. Schwager and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Amber B. Koehler

26 papers receiving 334 citations

Peers

Amber B. Koehler

GENET

PFM

IMMUN

ONCOL

HEMAT

Polina Kaplan Poland

Aileen Cohen United States

Talha Munir United Kingdom

Niamh Appleby United Kingdom

G. Doreen te Raa Netherlands

Ana Isabel Teruel Spain

Juan Besalduch Spain

Olaf Determann Germany

Anna Wall United States

Polina Kaplan Poland

Amber B. Koehler

283 ×1.0

GENET

228 ×1.0

PFM

94 ×1.1

IMMUN

59 ×0.9

ONCOL

116 ×1.7

HEMAT

Citations per year, relative to Amber B. Koehler Amber B. Koehler (= 1×) peers Polina Kaplan

Countries citing papers authored by Amber B. Koehler

Since Specialization

Citations

This map shows the geographic impact of Amber B. Koehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amber B. Koehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amber B. Koehler more than expected).

Fields of papers citing papers by Amber B. Koehler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amber B. Koehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amber B. Koehler. The network helps show where Amber B. Koehler may publish in the future.

Co-authorship network of co-authors of Amber B. Koehler

This figure shows the co-authorship network connecting the top 25 collaborators of Amber B. Koehler. A scholar is included among the top collaborators of Amber B. Koehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amber B. Koehler. Amber B. Koehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Christopoulos, Georgios, Zachi I. Attia, Sara J. Achenbach, et al.. (2024). Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia. JACC CardioOncology. 6(2). 251–263. 9 indexed citations

Wang, Yucai, Betsy LaPlant, Sameer A. Parikh, et al.. (2024). Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 42(16_suppl). 7050–7050. 1 indexed citations

Huntington, Scott F., Stephen J. Schuster, Wei Ding, et al.. (2023). DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study. American Journal of Hematology. 98(5). 739–749. 7 indexed citations

Tsang, Mazie, Paul J. Hampel, Kari G. Rabe, et al.. (2023). A study of frontline therapy in adults >80 years with chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 41(16_suppl). 12057–12057.

Parikh, Sameer A., Scott C. Lester, Kari G. Rabe, et al.. (2023). Safety of concurrent use of radiotherapy for second primary malignancy (SPM) in patients with chronic lymphocytic leukemia (CLL) receiving novel agent therapy.. Journal of Clinical Oncology. 41(16_suppl). e19507–e19507. 1 indexed citations

King, Rebecca L., Paul J. Kurtin, Wei Ding, et al.. (2022). Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. Blood Cancer Journal. 12(1). 18–18. 10 indexed citations

Hampel, Paul J., Kari G. Rabe, Timothy G. Call, et al.. (2022). Combined ibrutinib and venetoclax for treatment of patients with ibrutinib‐resistant or double‐refractory chronic lymphocytic leukaemia. British Journal of Haematology. 199(2). 239–244. 14 indexed citations

Parikh, Sameer A., Kari G. Rabe, Neil E. Kay, et al.. (2021). The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood. 138(2). 149–159. 23 indexed citations

Wang, Yucai, Sutapa Sinha, Linda Wellik, et al.. (2021). Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer Journal. 11(5). 86–86. 19 indexed citations

10.

Parikh, Sameer A., Sara J. Achenbach, Timothy G. Call, et al.. (2020). The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Medicine. 9(10). 3390–3399. 39 indexed citations

11.

Archibald, William J., Kari G. Rabe, Brian Kabat, et al.. (2020). Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Annals of Hematology. 100(1). 143–155. 35 indexed citations

12.

Koehler, Amber B.. (2020). An oral drug for chronic lymphocytic leukemia. JAAPA. 33(2). 51–53. 1 indexed citations

13.

Wang, Yucai, Sameer A. Parikh, Timothy G. Call, et al.. (2020). Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. Blood. 136(Supplement 1). 3–4. 1 indexed citations

14.

Wang, Yucai, Sara J. Achenbach, Kari G. Rabe, et al.. (2020). Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index (CLL-IPI).. Journal of Clinical Oncology. 38(15_suppl). 8026–8026. 1 indexed citations

15.

Archibald, William J., Kari G. Rabe, Brian Kabat, et al.. (2019). Atrial fibrillation (AF) in patients with CLL treated with ibrutinib: Assessing prediction models and clinical outcomes.. Journal of Clinical Oncology. 37(15_suppl). 7522–7522. 2 indexed citations

16.

Hampel, Paul J., Wei Ding, Timothy G. Call, et al.. (2019). Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leukemia & lymphoma. 60(11). 2712–2719. 42 indexed citations

17.

Wang, Yucai, Kari G. Rabe, Timothy G. Call, et al.. (2019). Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 105(3). 765–773. 76 indexed citations

18.

Hampel, Paul J., Timothy G. Call, Sara J. Achenbach, et al.. (2019). BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. Blood. 134(Supplement_1). 3050–3050. 3 indexed citations

19.

Hampel, Paul J., Timothy G. Call, Eli Muchtar, et al.. (2019). PS1162 COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). HemaSphere. 3(S1). 527–528. 1 indexed citations

20.

Archibald, William J., Wei Ding, Timothy G. Call, et al.. (2019). PF385 ANTICOAGULATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH IBRUTINIB. HemaSphere. 3(S1). 144–145.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact